| Literature DB >> 20491655 |
Eskouhie Tchaparian1, Lisa Marshal, Gene Cutler, Kathryn Bauerly, Winyoo Chowanadisai, Michael Satre, Calliandra Harris, Robert B Rucker.
Abstract
PQQ (pyrroloquinoline quinone) improves energy utilization and reproductive performance when added to rodent diets devoid of PQQ. In the present paper we describe changes in gene expression patterns and transcriptional networks that respond to dietary PQQ restriction or pharmacological administration. Rats were fed diets either deficient in PQQ (PQQ-) or supplemented with PQQ (approx. 6 nmol of PQQ/g of food; PQQ+). In addition, groups of rats were either repleted by administering PQQ to PQQ- rats (1.5 mg of PQQ intraperitoneal/kg of body weight at 12 h intervals for 36 h; PQQ-/+) or partially depleted by feeding the PQQ- diet to PQQ+ rats for 48 h (PQQ+/-). RNA extracted from liver and a Codelink(R) UniSet Rat I Bioarray system were used to assess gene transcript expression. Of the approx. 10000 rat sequences and control probes analysed, 238 were altered at the P<0.01 level by feeding on the PQQ- diet for 10 weeks. Short-term PQQ depletion resulted in changes in 438 transcripts (P<0.01). PQQ repletion reversed the changes in transcript expression caused by PQQ deficiency and resulted in an alteration of 847 of the total transcripts examined (P<0.01). Genes important for cellular stress (e.g. thioredoxin), mitochondriogenesis, cell signalling [JAK (Janus kinase)/STAT (signal transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) pathways] and transport were most affected. qRT-PCR (quantitative real-time PCR) and functional assays aided in validating such processes as principal targets. Collectively, the results provide a mechanistic basis for previous functional observations associated with PQQ deficiency or PQQ administered in pharmacological amounts.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20491655 PMCID: PMC2907713 DOI: 10.1042/BJ20091649
Source DB: PubMed Journal: Biochem J ISSN: 0264-6021 Impact factor: 3.857
PQQ status, body weight, liver/body weight ratio, plasma PQQ levels and liver mtDNA/nuclear DNA ratios
PQQ+, values for rats fed on an ASD containing 2 mg/kg PQQ; PQQ−, values for rats fed on an ASD devoid of PQQ; PQQ+/−, values for rats subjected to a short-term PQQ depletion (48 h); PQQ−/+, values for rats subjected to a PQQ repletion via intraperitoneal injection at 1.5 mg of PQQ/kg of body weight every 12 h for a period of 36 h. The relative amounts of liver mitochondrial DNA (mtDNA) and nuclear DNA measured by real-time PCR. The targeted genes were the nuclear CF and the mitochondrial ND-5 gene. Values within each row labelled with differing superscript letters indicate a difference between the groups of P<0.05 using a Dunnett's test.
| PQQ treatment group | |||||
|---|---|---|---|---|---|
| Parameter | PQQ+ | PQQ− | PQQ+/− | PQQ−/+ | LC |
| Body weight (g) | 220±11a | 225±16a | 221±13a | 231±8a | 250±22a |
| Liver/body weight (% relative to LC values) | 96±5a | 82±4 b | 101±4a | 91±4a | 100±5a |
| Plasma PQQ (nM) | 12±3a | 1.5±2.0b | 8±4a | 17±7a | 4.0±2.0b |
| Liver mtDNA/nuclear DNA | 1.05±0.24a | 0.76±0.13b | 0.82±0.2a,b | 1.3±0.2a | 1.1±0.2a |
Metabolic stress, cell signalling and immune function-related genes influenced by changes in PQQ status
An asterisk (*) indicates a significant increase or decrease in gene expression relative to values for the corresponding control group. The analysis was performed by means of SAM analysis using the Integromics Biomarker Discovery microarray data analysis software. Values within each row labelled with differing superscript letters indicate a difference between the groups of P<0.05 using a Dunnett's test. CaM, calmodulin; CDK, cyclin-dependent kinase; CTL, cytotoxic T-cell; IL, interleukin; NF-κβ, nuclear factor κB; NMDA, N-methyl-D-aspartate; PG, prostaglandin; SAPK, stress-activated protein kinase; TGF, transforming growth factor; TNF, tumour necrosis factor.
| PQQ treatment group (fold change relative to PQQ+) | ||||
|---|---|---|---|---|
| Gene | PQQ− | PQQ+/− | PQQ−/+ | Associated functions |
| Metabolic stress and apoptosis-related genes | ||||
| UVB radiation-activated UV96 mRNA | −5.1*a | 1.3b | 7.8*c | UV radiation-induced cellular stress-associated gene |
| Integrin-associated protein | −4.3*a | 1.1b | 6.3*c | Regulation of NF-κβ |
| Receptor-interacting serine-threonine kinase 3 | −2.1*a | 1.0a,b | 1.3b | Apoptosis, component of the TNF receptor-I signalling complex |
| Huntingtin-interacting protein | −2.1*a | −1.6a | 5.6*b | Associated with apoptosis |
| BAX | −2.0a | 1.6b | 8.0*c | Pro-apoptotic regulator that is involved in a wide variety of cellular activities (e.g. mitochondrial membrane porosity) |
| Catechol-O-methyl transferase | −1.5a | 13.6*b | 27.8*c | Cellular stress; involved in IL-1 signalling |
| Smad 5 | −1.2a | −1.4a | 3.2*b | Modulation of TGF-β ligands |
| STAT3 | −1.2a | −1.2a | 7.3*b | Transcription acute-phase response factor that is activated by nuclear co-activator 1 |
| Lyric | −1.2a | 1.1a | 4.1*b | Activates the NF-κβ transcription factor |
| D-site albumin promoter-binding protein | 4.8*a | −2.7*b | −5.9*b | Transcription factor; down-regulation is associated with reduced metabolic stress and apoptosis |
| p75-like apoptosis-inducing death domain protein | 2.7*a | −1.2b | −3.0*c | Apoptosis; is expressed in high amounts in the embryonic tissue and down-regulated in adult tissue |
| 5-Hydroxytryptamine (serotonin) receptor 1F | 1.5a | −1.5a | −3.6*c | Serotonin receptor |
| Heat-shock factor 2 | 1.2a | 1.2a | 2.6*b | Stress-related chaperon transport functions |
| Neuraminidase 2 | 1.1a | −2.9*b | −2.4*b | Sialidase (cleaves neuraminic acid glycosidic linkages), important to the mobility of virus and related particles |
| Prostaglandin D2 synthase | 1.0a | 1.2a | −2.4*b | Glutathione-independent prostaglandin D synthase that catalyses the conversion of PGH2 into PGD2 |
| MAPK and MAPK phosphatases | ||||
| Receptor-interacting serine/threonine kinase 3 | −2.1*a | 1.0b | 1.3b | Component of the TNF receptor-I signaling complex |
| 3-Phosphoinositide-dependent protein kinase-1 | −1.6a | −1.4a | 3.1*b | Signalling processes important for development; activates various MAPK signalling pathways |
| Dual-specificity phosphatase 7 | −1.3a | −1.7a | 2.1*b | Negatively regulate the activity of MAPKs in response to changes in the cellular environment (e.g. heat or metabolic stress) |
| MAPKKK12 | −1.2 a | −1.3a | 3.1*b | An activator of the JNK/SAPK pathway |
| Tyrosine protein kinase pp60 | −1.1a | −1.1a | 2.9*b | A protein kinase C (Ca2+/phospholipid-dependent); known to phosphorylate epidermal growth factor receptor and reduce its affinity for epidermal growth factor |
| Serine/threonine kinase 3 | 2.8*a | 3.2*a | −3.0*b | MAPK that is activated in response to cellular stress |
| MAPK phosphatase | 2.0*a | 1.0a | −2.6*b | Up-regulated during stress; modulates MAPK activities that are sensitive to changes in the cellular environment |
| Protein tyrosine phosphatase 4a1 | 1.5a | −1.6b | −2.8*c | Up-regulated during stress; modulates MAPK activity |
| Cyclin A2 | 1.3a | 1.5a | −3.7*b | Regulators of CDK kinases important to the temporal co-ordination of mitotic events |
| RAS p21 protein activator 1 | 1.2a | −1.2a | −4.0*b | Cytoplasmic GAP1 family of GTPase-activating proteins important to cell proliferation; most abundant in embryonic tissue |
| CaM-kinase II inhibitor | 1.0a | −1.4a | 3.1*b | Serine/threonine protein kinase inhibitor in the Ca2+/CaMdependent protein kinase subfamily |
| MAPK14 | 1.3a | −3.9*b | −2.7*b | A p38 kinase, activated by cellular stress; MAPK 14 activates ERK and kinases in Ras-oncogene related pathways |
| Immune and neural function | ||||
| Cathepsin H | −2.6*a | −4.3*b | 2.4*c | Lysosomal cysteine proteinase |
| Lysozyme | −2.4*a | −1.7*a | 4.0*b | A major component of the innate immune system |
| CTL target antigen | −2.3*a | −1.4b | 1.8*c | Antigen to killer T-cells |
| Complement component 1 | −2.2*a | −1.1b | 1.3c | Important for the complement fixation sites of immunoglobulin |
| Transcription factor 4 | −2.2*a | −1.7*a | 7.0*b | Immune function |
| STAT5B | −2.0*a | −1.2a | 1.6b | T-cell receptor signalling, apoptosis, sexual dimorphism of liver gene expression |
| Basigin | −1.4a | 1.7b | 3.8*b | Member of the immunoglobulin super family with a number of functions (e.g. lymphocyte recognition) related to early development |
| CD14 antigen | −1.7*a | −1.1b | 1.5b,c | Immune response |
| MHC II, DM β class II | −1.7*a | −1.1b | 2.2*c | Immune response |
| JAK3 | 1.0a | 1.6a | 2.3*b | Transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors; mutations of JAK3 result in severe immunodeficiency; mice that do not express JAK3 have T-cells and B-cells that fail to respond to many cytokines |
| Presenilin 1 | −3.6*a | −1.6b | 2.4*c | Proteinase associated with amyloidal protein defects |
| RAF-1 | −1.6a | 1.1a | 15.5*b | Receptor important for cellular proliferation and regulation by neuregulins, important for the development of the nervous system |
| Ninjurin | −1.6a | 1.0a | 3.1*b | Nerve injury-induced protein involved in nerve regeneration and in their formation |
| Neuropilin | −1.1a | 1.2a | 5.8*b | Semaphorin binding is especially important in neural system development |
| Cholinergic receptor, nicotinic, α polypeptide 1 | −1.1a | −1.6a,b | −2.0*b | Acetylcholine receptors |
| Neurotrophin-3 | 3.6*a | 2.2*a | 1.1b | Protein growth factors important to peripheral and central nervous system function |
| Benzodiazepine receptor | 2.7*a | −1.4b | −2.0*b | Enhances the effects of the neurotransmitter γ-aminobutyric acid |
| Plexin A3 | 2.0*a | −1.1b | −5.0*c | Interacts with RAC-α serine/threonine protein kinase, a mediator of growth factor-induced neuronal survival |
| Glutamate receptor, ionotropic, NMDA2B | 1.0a | 1.5a | −4.7*b | NMDA receptor important for synaptic transmissions |
| Cholinergic receptor, nicotinic, β polypeptide 1 | 1.4a | 1.1a | −2.6*b | Acetylcholine receptor |
Cellular transport, assembly, growth, cell cycling and extracellular matrix formation genes influenced by changes in PQQ status
An asterisk (*) indicates a significant increase or decrease in gene expression relative to values for the corresponding control group. The analysis was performed by means of SAM analysis using the Integromics Biomarker Discovery microarray data analysis software. Values within each row labelled with differing superscript letters indicate a difference between the groups of P<0.05 using a Dunnett's test. ABC, ATP-binding-cassette; CDK, cyclin-dependent kinase; DMT, divalent metal transporter; ER, endoplasmic reticulum; MARCKS, myristoylated alanine-rich protein C-kinase substrate; SNAP, soluble N-ethylmaleimide-sensitive fusion protein-attachment protein; VAMP, vesicle-associated membrane protein.
| PQQ treatment group (fold change relative to PQQ+) | ||||
|---|---|---|---|---|
| Gene | PQQ− | PQQ+/− | PQQ−/+ | Associated functions |
| Transport | ||||
| Solute carrier family 28, member 2 | −2.1*a | 1.0b | 1.0b | Sodium-coupled nucleoside transporter |
| Solute carrier family 34, member 2 | −2.0*a | 2.2*b | 4.2*c | Sodium-dependent phosphate transport |
| Transporter 1, ATP-binding cassette, subfamily B | −2.8*a | 1.3b | 2.3*c | Member of the ABC transport family; cholesterol efflux regulatory protein |
| Embigin 5 | −2.0*a | 1.2a | 1.5b | Monocarboxylate transporter |
| DMT1-associated protein | −1.2a | −1.1a | 2.1*b | Divalent metal ion (e.g. Fe2+) transporter |
| Aquaporin 8 | −2.2*a | 1.0b | 3.6*c | Water transport; localized in the inner mitochondrial membrane |
| Solute carrier family 2, member 13 | 1.3a | 1.1a | −3.3*b | Member of the facilitated glucose transporter family |
| Solute carrier family 4, member 4 | 1.0a | −1.1a | 3.4*b | Electrogenic sodium bicarbonate co-transporter |
| Solute carrier family 4, member 1 | 1.6a | −2.2*b | −4.0*c | Chloride-bicarbonate cotransporter |
| Solute carrier family 6 | 1.3a | 1.0a | −2.7*b | Co-transport of Na+ and Cl− and neurotransmitter molecules (family includes carriers for -aminobutyric acid, noradrenaline/adrenaline, dopamine, serotonin, proline, glycine, choline, betaine and taurine) |
| Solute carrier family 14, member 2 | 1.2a | −5.6*b | −1.2a | Urea transporter |
| Solute carrier family 17 | 1.2a | 1.0a | 6.5*b | Phosphate transporter |
| Solute carrier family 18 | 2.3*a | −1.6b | −6.8*c | Vesicular monoamine transporter |
| Solute carrier family 20, member 1 | 1.7*a | −1.1a | −3.0*c | Phosphate transporter |
| Similar to solute carrier family 2, member 5 | 2.4*a | 2.5*a | −1.4b | Integral membrane transporter, similar to those in the facilitated glucose transporter family |
| Similar to solute carrier 37 | 1.2a | −1.3a | −2.0*b | Glycerol 3-phosphate transporter |
| Cellular assembly | ||||
| Epimorphin | −2.5*a | 1.1b | 2.3b | Intracellular vesicle docking |
| MARCKS-like protein | −1.9*a | 1.0b | 1.0b | Interacts with dynactin, ER-to-Golgi transport |
| Signal transducer and activator of transcription 5B | −2.0*a | −1.2a | 1.6b | Activation of tethering signalling components, apoptosis |
| Epimorphin | −1.2a | 1.3a | 2.3*b | Intracellular vesicle docking protein |
| Golgi SNAP protein, member 2 | −1.2a | −1.9a | 5.4*b | Trafficking of membrane proteins that travel among the medial- and |
| GTPase Rab8b | −2.3*a | −2.0*a | 2.9*b | Rab GTPases regulate many steps of membrane trafficking: vesicle formation, vesicle movement along actin and tubulin networks, and membrane fusion |
| Transgelin | −1.6a | −1.0a | 3.4*b | Transformation and shape-change; actin cross-linking/gelling |
| Karyopherin α2 | −1.0a | 1.0a | 3.0*b | Involved in transporting molecules through the pores of the nuclear envelope: a part of the importin-β superfamily |
| | 4.7*a | 1.1b | 1.3b | |
| Chimerin 1 (Chimaerin) | 2.9*a | 1.4b | −6.3*c | Regulation of Rac, a subfamily of the Rho family GTPases involved in cell organization and regulation |
| Chimerin 2 | 1.6a | −1.4a | −4.9*c | Induces translocation of the protein from the cytosol to the Golgi apparatus |
| Heat-shock 27 kDa protein family, member 3 | 1.4a | −1.1a | −3.5*b | Hsp27 functions as a molecular chaperone and is involved in the regulation of cell growth and differentiation |
| ADP-ribosylation factor guanine-nucleotide exchange factor 2 (brefeldin A-inhibited) | 1.4a | 1.0a | −1.9*b | Intracellular vesicular trafficking |
| Dynactin 4 | 1.1a | 1.1a | −2.3*b | Aids in bidirectional intracellular organelle transport by binding to dynein and kinesin II and linking them to the organelles to be transported |
| GRB2-associated binding protein 2 | 1.6a | 1.5a | −2.6*b | Principal activator of phosphatidylinositol 3-kinase involved in cellular growth, proliferation, motility and intracellular trafficking |
| Vesicle-associated membrane protein 8 | −1.2 a | 1.2 a | 2.3*b | Synaptobrevins/VAMPs, syntaxins and the 25-kDa synaptosomalassociated proteins (SNAP25) are components involved in the docking and/or fusion of synaptic vesicles with the presynaptic membranes |
| Growth, cell cycling and extracellular matrix formation | ||||
| Connective tissue growth factor | −3.1*a | −1.2b | 4.3*c | Cellular matrix induction |
| Collagen type XXVII | −2.9*a | −1.2b | 3.8*c | In the ‘fibrillar’ class of collagens |
| Prolyl 4-hydroxylase α subunit | −3.1*a | −3.1*a | 3.4*b | Catalyses the formation of 4-hydroxyproline |
| Cyclin D2 | −1.2 a | −1.1 a | 2.5*b | Regulation of transcription and mRNA processing |
| Cyclin-dependent kinase inhibitor 1C, p57 | −1.2 a | 1.4 a | 2.7*b | A negative regulator of cell proliferation |
| Septin-like protein | −1.1 a | 1.2 a | 1.9*b | Apparent cell division cycle regulatory protein |
| Similar to methionyl-tRNA synthetase | 3.9*a | −1.7 | −14.7 | Apparent relationship with protein translation |
| p21 (CDKN1A)-activated kinase 2 | 1.0a | −1.2a | −2.3*b | Kinase in the CDK important for cell cycling |
| Cyclin A2 | 1.3a | 1.5a | −3.7*b | Cyclins function as regulators of CDKs; CDKs are involved in the regulation of transcription and mRNA processing |
| p21 (CDKN1A)-activated kinase 3 | 2.1*a | −1.2b | −8.0*c | Tightly controlled by p53; important for cell cycling and G1-phase arrest in response to a variety of stress stimuli |
| Prominin | 1.3 a | −9.0*b | −29.8*c | Localizes to cellular protrusions in haemopoietic and neuronal stem cells |
| Integrin α E1 | 1.1 a | 1.0a | 2.4*b | One of many integrin receptors that mediate attachment between a cell and the tissues |
| Lamin B receptor | 2.3*a | −1.8*b | −6.5*c | Aids in anchoring the lamina and heterochromatin to cellular membranes |
| Chondroadherin | 1.3 a | −1.9*b | −5.1*c | Binds cells via the integrin α-family of receptors and controls cell spreading |
| Chondroitin sulfate proteoglycan 3 | 1.3 a | −1.6a | −2.1*a,b | Cell matrix component |
Mitochondrial, secondary metabolism and lipid-related genes influenced by changes in PQQ status
An asterisk (*) indicates a significant increase or decrease in gene expression relative to values for the corresponding control group. The analysis was performed by means of SAM analysis using the Integromics Biomarker Discovery microarray data analysis software. Values within each row labelled with differing superscript letters indicate a difference between the groups of P<0.05 using a Dunnett's test. HO, haem oxygenase; IL, interleukin.
| PQQ treatment group (fold change relative to PQQ+) | ||||
|---|---|---|---|---|
| Gene | PQQ− | PQQ+/− | PQQ−/+ | Associated functions |
| Mitochondrial and metabolism-related | ||||
| Mitochondrial tumour suppressor gene 1 | 1.7*a | 1.3a | −1.7*b | Mitochondrial-related apoptosis |
| STAT3 | −1.4a | 1.1a | 7.0*b | Interacts with IL-6; required for optimal mitochondrial function |
| ATP synthase, H+ transporting, mitochondrial F1 complex, γ polypeptide 1 | −1.4a | −1.1a | 2.0*b | Subunit of mitochondrial ATP synthase |
| ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit | −1.3a | 1.2a,b | 1.8b* | Subunit of mitochondrial ATP synthase |
| ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide | 1.0a | −1.2a | 2.5*b | Subunit of mitochondrial ATP synthase |
| ATP synthase, H+ transporting, mitochondrial Fo complex, subunit c, isoform 1 (5 other subunitsdetected) | −1.1a | 1.2a | 2.3*b | Subunit of mitochondrial ATP synthase |
| ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9) | 1.0 a | 1.1a | 2.3*b | Subunit of mitochondrial ATP synthase |
| Cytochrome | −1.1a | 1.2a | 2.6*b | Subunit of cytochrome |
| Cytochrome | −1.1a | −1.1a | 2.3*b | Subunit of cytochrome |
| HO-1 | −1.7 *a | −1.1a | 1.9*b | HO-1 is a protective antioxidant enzyme that prevents apoptosis; inducible |
| HO-2 | 1.1a | −1.1 a | −1.2a | Constitutive HO involved in haem catabolism used a control for HO-1 and HO-3 |
| HO-3 | −3.2*a | −1.4b | 22.9*c | HO-3 is not catalytically active, but is thought to function as an oxygen sensor |
| Hypoxia-inducible factor 1 | 1.0a | −1.2 a | −2.3*b | Functions as an oxygen sensor |
| Phosphoserine aminotransferase 1 | −6.7*a | −1.0a | 3.4*b | Formation of phosphoserine from 3-phosphohydroxypyruvate |
| Glycerol kinase | −2.5*a | 1.0b | 2.3*c | Triacylglycerol formation |
| Succinyl-CoA ligase (ATP-forming), β chain | −1.4a | 1.0a | 2.3*b | Energy production and conversion |
| Glucokinase regulatory protein | −1.7a | 1.3b | 4.7*c | Glucokinase/glucose regulation |
| Glucokinase | −1.9*a | −2.9*b | 2.1*c | Glucose regulation |
| Fructose-2,6-biphosphatase 4 | −1.9*a | 1.6b | 3.2*c | Important for glycolysis and gluconeogenesis |
| Glutamate oxaloacetate transaminase 2 | 1.3a | 1.6a | 1.3a | Amino acid metabolism |
| D-site albumin promoter-binding protein | 4.5*a | −2.8*b | −5.7*c | A member of the proline and acidic amino acid-rich basic leucine zipper transcription factor family; binds to an upstream promoter in the insulin gene |
| Glycogen synthase 2 | 1.7a | −1.1b | −2.6*c | Regulation of glycogen synthesis |
| Pyruvate dehydrogenase phosphatase isoenzyme 1 | 1.0a | −1.1a | −2.7*b | Energy production and conversion |
| Ornithine decarboxylase | 1.4a | 1.0a | −2.3*b | Urea cycle regulation |
| Serine dehydratase | 5.5*a | −1.4b | −3.7*c | Converts serine into pyruvate; threonine into propionyl-CoA |
| Secondary metabolism-related | ||||
| Thioredoxin 2 | −1.1a | 1.1a | 2.2*b | Contributes to antioxidant activity by facilitating the reduction of proteins by cysteine thiol–disulfide exchange |
| Aryl hydrocarbon receptor nuclear translocator | −8.7*a | −1.1b | 9.6*b | Induction of enzymes important to xenobiotic metabolism; forms a complex with ligand-bound aryl hydrocarbon receptors required for receptor function |
| Cytochrome P4508B1 hydrolase | −2.8*a | 1.2b | 2.5*b | Phase 1 xenobiotic metabolism |
| Cytochrome P4504A3 hydrolase | −1.4a | 2.1*b | 3.6*b | Phase 1 xenobiotic metabolism |
| Cytochrome P4507A1 hydrolase | −2.1*a | −3.0*b | −3.0*b | Phase 1 xenobiotic metabolism |
| Cysteine–sulfinate decarboxylase | −4.5*a | −1.0b | 1.0b | Hypotaurine metabolism |
| Glutathione transferase, mu 5 | −1.2a | −1.2a | 2.4*b | Phase II reaction functions |
| Lipid and phospholipid-related | ||||
| Fatty acid elongase 2 | −1.2a | 2.5*b | 12.5*c | Fatty acid chain elongation |
| Fatty acid desaturase | −2.0*a | −1.2b | 1.9*c | Formation of unsaturated acyl chains in fatty acids |
| Carnitine-O-octanoyl transferase 1 | −2.0*a | 1.6b | 1.9*b | Mitochondrial transport fatty acid transport enzyme |
| Adiponectin receptor 2 | −1.4a | 1.1a | 2.8*b | Receptor for adiponectin binding; levels of adiponectin are inversely correlated with body fat percentage in adults |
| Choline kinase | −2.1*a | 1.3*b | 1.6b | Participates in glycine, serine and threonine and glycerophospholipid metabolism |
| Mevalonate pyrophosphate decarboxylase | −1.9*a | −1.1a | 2.0*b | Enzyme in the mevalonate pathway |
| HMG-CoA lyase | −1.4a | 1.0a | 2.4*b | Cholesterol biosynthesis |
| Farnesyl diphosphate synthase | −1.4a | 1.7b | 2.0*b | Conversion of geranyl diphosphate and isopentenyl diphosphate into farnesyl diphosphate |
| 2,3-Oxidosqualene:lanosterol cyclase | −1.4a | −2.1*a | 1.4b | Cholesterol synthesis |
| Isopentenyl-diphosphate Δ isomerase | −1.9*a | −1.6a | 1.8*b | Steroid synthesis regulation |
| 2,3-Oxidosqualene:lanosterol cyclase | −1.7*a | −1.4a | 1.4a | Steroid synthesis |
| Cytochrome P4508B1, sterol 12α hydrolase | −2.7*a | 1.2b | 3.0*c | Steroid synthesis |
| Lipocalcin 2 | 1.4a | −1.6b | 5.4c | Transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids |
| Leptin receptor | 2.0*a | 1.3a | −2.0*b | Regulates adipose-tissue mass through hypothalamic effects on satiety and energy expenditure |
| Sphingomyelin phosphodiesterase | 2.0*a | 1.0a,b | −1.4b | Sphingomyelin regulation; sphingomyelin is converted into phosphocholine and ceramide |
| Ng22 protein | 1.8*a | −1.4b | −2.1*b | Choline transporter-like protein 4, phospholipid metabolism |
| CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 | 1.3a | 1.3a | −1.8*b | A CTP-diacylglycerol or diacylglycerol synthetase that participates in glycerophospholipid metabolism and phosphatidylinositol signaling systems |
| Sphingolipid G-protein-coupled-receptor 5 | 1.5a | −2.9*b | −3.3*b | Lipid signaling molecule that binds sphingosine 1-phosphate |
| Lysophospholipase | 1.9*a | 1.4a | 1.3b | Glycerophospholipid metabolism; converts 2-lysophosphatidylcholine into glycerophosphocholine |
| Monoacylglycerol lipase | 1.0a | −1.4a | 3.6*b | Functions together with hormone-sensitive lipase to hydrolyse intracellular triacylglycerols |
| Fatty acid CoA ligase, long chain 5 | 1.3a | 2.5*b | 4.0*c | Conversion of long-chain fatty acids into acyl-CoA esters |
| Stearoyl-CoA desaturase 2 | 2.1*a | 4.0*b | −1.2c | A Δ9-fatty acid desaturase |
| Phosphatidylinositol-binding clathrin assembly protein | 1.0a | −1.2a | 1.9*b | Clathin assembly and phospholipid metabolism |
Figure 1Network-assisted transcription profiling
PQQ-influenced genes belong to multiple activity categories. The −log of the P-values relative to the PQQ+ group are indicated, with P<0.05 denoted by the vertical grey line. Dietary groups correspond to: PQQ-deficient (PQQ−), black bars; short-term PQQ-deficient group (PQQ+/−), grey bars; and PQQ-repleted (PQQ−/+), white bars. (A) Canonical clusters and relationships and (B) potential pathways and processes affected by PQQ. NS (not significant) indicates P>0.4.
Figure 2qRT-PCR validation of selected genes
Expression profiles were obtained for carnitine-O-octanoyltransferase, HMG-CoA lyase, CYP4a3, CYP7a1, glucokinase, lipocalin 2, monoacylglycerol lipase, Raf1, and STAT3 and closely match the profiles observed in the microarray analysis (Tables 1–4). Values represent fold changes in expression relative to a corresponding control group. Ratios: Control, PQQ+/PQQ+ (=1.0), PQQ deficient, PQQ−/PQQ+ (white bars); PQQ partially depleted PQQ(+/−)/PQQ+ (black bars); PQQ-repleted PQQ(−/+)/PQQ− (grey bars).
Figure 3NPY, c-fos, mtDNA/nuclear DNA ratio, and relative changes in succinic acid dehydrogenase, citrate synthetase, cytochrome oxidase-related transcripts, PGC-1α and Tfam in response to dietary PQQ status
(A) Changes in NPY and c-fos levels in response to changes in PQQ exposure. Values represent fold changes in expression relative to a corresponding control group. Ratios: Control, PQQ+/PQQ+ (=1.0), PQQ deficient, PQQ−/PQQ+ (white bars); PQQ partially depleted PQQ(+/−)/PQQ+ (black bars); PQQ-repleted PQQ(−/+)/PQQ− (grey bars). The superscript letter values indicate that there was a difference between groups (P<0.05 using a Dunnett's post-test). (B) Plasma PQQ and the relative content or fold changes for liver mtDNA and succinic acid dehydrogenase (SDH), citrate synthetase (CS) and cytochrome oxidase-related transcripts (Cyt OX). Values for r2 (plasma PQQ compared with relative fold-changes) ranged from approx. 0.72 to 70.95. (C) Relationship of Tfam to PGC-1α (relative changes in transcript levels) in PQQ− rats (□) or PQQ+ rats (●). Changes in PGC-1α and Tfam transcripts levels (estimated by qRT-PCR) and the mtDNA/nuclear DNA ratio are expressed as a percentage of control values (insert). *P<0.05; **P<0.2.
Figure 4Plasma sphingomyelin and triacylglycerol levels
PQQ exposure had a significant effect on plasma sphingomyelin and triacylglycerol levels. The superscript letters indicate that there was a difference between groups (P<0.05 using a Dunnett's post-test). The major fatty acid classes contained in the sphingomyelin and triacylglycerol fractions are: polyunsaturated fatty acids (black), mono-unsaturated fatty acids (grey) and saturated fatty acids (white bars). Results are means+S.E.M (n=6).
Figure 5Proposed pathways regulated by dietary PQQ
Several major signalling pathways are modulated by changes in PQQ dietary status. Given the broad range of responses, PQQ is proposed to bind to a cell surface receptor that triggers responses from one or more transducers. The JAK/STAT3 pathway is highlighted, because STAT3 is up-regulated and influences the expression of a variety of genes that play key roles in cellular processes such as cell proliferation, differentiation and apoptosis. The link to AMPK is based in part on the down-regulation of NPY. Cross-talk between Raf-1 and STAT3 is inferred (broken arrow), because of the known inter-relationships between MAPK/ERK signalling and STAT3, and the up-regulation of c-Fos, Raf-1 and Ras following exposure to either dietary or pharmacological levels of PQQ. The MAPK p58 family (e.g., MAPKKK12 and MAPK14) is also involved. The combination of the two cell signalling pathways can lead to the up-regulation or activation of PGC-1α, PPARα (peroxisome-proliferator-activated receptor α) and CREB as end products.